Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441141 · ClinicalTrials.gov registry record
Genetics and Pain Severity in Sickle Cell Disease
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 67
- Enrollment target
NCT01441141 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 67 participants.
The verdict
NCT01441141 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Background: \- Pain is the most common symptom of sickle cell disease. Episodes of severe sickle cell pain are known as "crises." High rates of pain crises are associated with a higher risk of early death. Some people with sickle cell disease have many severe pain crises while others experience fewer crises. This difference in pain crisis may be caused by sensitivity to pain. People with high sensitivity to pain may have more pain crises. Many factors, including a person's genetic makeup, determine sensitivity to pain. Comparing genetic information from people with sickle cell disease and healthy volunteers may provide more information on pain and sickle cell disease. Objectives: \- To study genetics and pain sensitivity in sickle cell disease. Eligibility: * African or African American individuals at least 18 years of age with sickle cell disease. * Healthy African or African American volunteers at least 18 years of age. Design: * Participants will be screened with a medical history and physical exam. They will also provide blood and urine samples. * Participants will have the following tests: * Quantitative sensory testing to measure sensitivity to pressure, heat, cold, and mechanical pain. * EndoPat test to measure blood vessel function and reaction. * Questionnaires about mood, evidence of depression, pain, quality of sleep, and sleep disturbances. * Measures of daily pain, whether or not related to sickle cell disease. * After the first visit, those in the study will have monthly study visits for 6 months. The above tests will be repeated at these visits.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2012-06-17 |
| Est. Completion | 2020-12-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441141
The ClinicalTrials.gov registry entry for NCT01441141 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01441141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441141 about?
NCT01441141 is a clinical study titled "Genetics and Pain Severity in Sickle Cell Disease". Background: \- Pain is the most common symptom of sickle cell disease. Episodes of severe sickle cell pain are known as "crises." High rates of pain crises are associated with a higher risk of early death. Some people with sickle cell disease have many severe pain crises while others experience few...
What is the current status of trial NCT01441141?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2012-06-17. Estimated completion is 2020-12-09.
Who is sponsoring clinical trial NCT01441141?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.